<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307279</url>
  </required_header>
  <id_info>
    <org_study_id>G-04</org_study_id>
    <nct_id>NCT02307279</nct_id>
  </id_info>
  <brief_title>Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gelesis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gelesis, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will asses the decrease in body weight after repeated administration of Gelesis100&#xD;
      in overweight and obese subjects with and without Type 2 Diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To asses the decrease in body weight after repeated administration of Gelesis100 in&#xD;
      overweight and obese subjects with and without Type 2 Diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Co-Primary Outcome: Placebo-adjusted percent weight loss</measure>
    <time_frame>Percentage change from Baseline to Day 171</time_frame>
    <description>super-superiority margin of 3% in addition to superiority as of 02/2016</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-Primary Outcome: Weight loss of at least 5% in greater than or equal to 35% of subjects on Gelesis100</measure>
    <time_frame>5% weight loss from Baseline to Day 171</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent body weight change in subjects with impaired plasma glucose status at baseline</measure>
    <time_frame>Baseline to Day 171</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma glucose status (normal, impaired, diabetic) in subjects with impaired plasma glucose status at baseline</measure>
    <time_frame>Baseline to Day 171</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in plasma glucose in subjects with impaired plasma glucose status and type 2 diabetes at baseline</measure>
    <time_frame>Baseline to Day 171</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
    <time_frame>Baseline to Day 171</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c in subjects with type 2 diabetes at baseline</measure>
    <time_frame>Baseline to Day 171</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess safety and tolerability of administration of Gelesis100</measure>
    <time_frame>Baseline to Day 197</time_frame>
    <description>Adverse Events (AEs), Physical Examinations, Vital Signs, Laboratory Tests</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">436</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Gelesis100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gelesis100 twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gelesis100</intervention_name>
    <arm_group_label>Gelesis100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 22 to 65 years of age, inclusive&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
          -  BMI 27 to 40, inclusive (BMI of &lt;30 should have at least one comorbidity)&#xD;
&#xD;
          -  Fasting plasma glucose 90mg/dL to 145 mg/dL, inclusive; non-diabetic normoglycemic&#xD;
             (fasting glucose 90 mg/dL to 100 mg/dL, inclusive); non-diabetic impaired fasting&#xD;
             glucose 100mg/dL to 126 mg/dL; and diabetic: untreated (126 mg/dL to 145 mg/dL,&#xD;
             inclusive) and metformin-treated (metformin dose 1500mg/DL and less, fasting glucose&#xD;
             less than 145 mg/dL, inclusive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Absence of medically approved contraceptive methods in females of childbearing&#xD;
             potential&#xD;
&#xD;
          -  History of allergic reaction to modified cellulose, citric acid, sodium stearyl&#xD;
             fumarate, raw cane sugar, gelatin, and titanium oxide&#xD;
&#xD;
          -  Administration of investigational products within 1 month prior to Screening Visit&#xD;
&#xD;
          -  Subjects who stopped smoking within 6 months prior to Screening Visit or considering&#xD;
             smoking cessation during the study&#xD;
&#xD;
          -  Subjects anticipating surgical intervention during the study&#xD;
&#xD;
          -  Known Type 1 diabetes&#xD;
&#xD;
          -  History of eating disorders&#xD;
&#xD;
          -  Angina, coronary bypass, or myocardial infarction within 6 months prior to Screening&#xD;
             Visit&#xD;
&#xD;
          -  History of: swallowing disorders, esophogeal anatomic abnormalities, gastroesophageal&#xD;
             reflux disease, gastric or duodenal ulcer, gastroparesis (chronic nausea, vomiting,&#xD;
             heartburn...), gastric bypass or other gastric surgery, intestinal obstruction or at&#xD;
             high risk of including suspected small bowel adhesion, pancreatitis, malabsorption,&#xD;
             history of bowel resection (except if related to appendectomy), history of abdominal&#xD;
             radiation treatment&#xD;
&#xD;
          -  Laxative users&#xD;
&#xD;
          -  History of: HIV, hepatitis B or C; cancer within the past 5 years&#xD;
&#xD;
          -  Abnormal serum thyroid-stimulating hormone (TSH)&#xD;
&#xD;
          -  Positive urine drug test&#xD;
&#xD;
          -  Anti-obesity medication within 1 month prior to Screening Visit (except stable doses&#xD;
             of metformin, no more than 1500 mg/day, for at leaset 1 month in subjects with type 2&#xD;
             diabetes)&#xD;
&#xD;
          -  Systemic corticosteroids within 1 month prior to Screening Visit&#xD;
&#xD;
          -  Thyroid hormones or preparations within 1 month prior to Screening Visit&#xD;
&#xD;
          -  Estrogen within 1 month prior to Screening Visit&#xD;
&#xD;
          -  Any other medication known to cause weight loss or weight gain within 1 month prior to&#xD;
             Screening Visit&#xD;
&#xD;
          -  TSH suppression therapy for thyroid cancer&#xD;
&#xD;
          -  medications requiring mandatory administration with meal (lunch or dinner), except&#xD;
             metformin&#xD;
&#xD;
          -  Other medication or product used for chronic diseases if their impaired&#xD;
             gastrointestinal absorption can cause safety issues&#xD;
&#xD;
          -  Change in medications treating hypertension and/or dyslipidemia within 1 month prior&#xD;
             to Screening Visit (including change in dose)&#xD;
&#xD;
          -  Anticipated requirement for use of prohibited concomitant medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan M Heshmati, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <zip>91307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1N 6N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Qu√©bec</city>
        <state>Quebec</state>
        <zip>G1V 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Hradec</city>
        <zip>500 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Prague</city>
        <zip>121 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Prague</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Prague</city>
        <zip>182 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Milan</city>
        <state>Milanese</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 26, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <disposition_first_submitted>May 14, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>May 14, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 20, 2019</disposition_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

